2020 AT A GLANCE

NET PRICES FOR OUR MEDICINES HAVE DECLINED...



Average net price decline of Janssen medicines in 20201



\$29.4B

Total amount Janssen paid in rebates, discounts and fees to payers and others in the health system in 2020²



-14.4%

Compound net price decline of Janssen medicines since the beginning of 2016³

BECAUSE OUR DISCOUNTS HAVE GROWN FROM 2016-2020*



3.3X Medicare⁴



2.2X

Medicaid⁶



4.2X **Commercial health** plans and PBMs⁵



2.6X 340B providers

More than half the list price of our medications went to payers and others in the health system8

DESPITE PRICE REDUCTIONS, BENEFIT DESIGNS PUT MORE FINANCIAL BURDEN ON PATIENTS



-5.7% Average net price decline of Janssen medicines in 20209



111% Average deductible amount increase for employer-sponsored insurance from 2010 (\$646) to 2020 (\$1,364)10



17% According to a study, increase in annual ER visits when co-pays are doubled for patients taking certain medications"

WE'RE SUPPORTING PATIENTS TODAY AND TOMORROW

Nearly **1.2 million** patients helped with **access, affordability and treatment** support through the Janssen CarePath Savings Program¹²

646,000 commercially insured patients **reduced their out-of-pocket costs** through the Janssen CarePath Savings Program¹³

8.1% increase in average R&D **investment** from 2016-2020¹⁴

 $\$\mathbf{9.6}$ B dedicated in 2020 to the discovery and development of new medicines and vaccines15

*By channel, growth rate in dollars of discounts provided, 2016-2020. For more detail, including discount rates, see pages 7-8 of the 2020 Janssen U.S. Transparency Report.

- Figure According to Janssen Internal Financial Accounting.
 Ibid.
- 3. Ibid.
- Ibid.
 Ibid.
- Ibid.
- 7. 8. Ibid Ibid.
- 10. The Henry J. Kaiser Family Foundation. "2020 Employer Health Benefits Survey." p.139. October 8, 2020. http://files.kff. org/attachment/Report-Employer-Health-Benefits-2020-Annual-Survey.pdf.
- 11. Jarvis, D. "How Are We Going to Get Paid Tomorrow? Emerging Models for Health and Behavioral Healthcare Working Draft." The College for Behavioral Health Leadership. March 18, 2020. https://www.leaders4health.org/wp-content/ uploads/2020/02/Jarvis_Getting_Paid.pdf.
- 12. Data are an approximate number of patients supported by Janssen CarePath provided by the program administrator.
- 13. Ibid.
- 14. Figure According to Janssen Internal Financial Accounting.
- 15. Johnson & Johnson, FY20-Q4 Form 10-K for the period ending January 3, 2021 (filed February 22, 2021).

pharmaceutical companies of Johnson janssen

© Janssen Pharmaceuticals, Inc. 2021 cp-217477v1